10.1016/j.asjsur.2023.09.145 64
MAOIs are also an older class of drugs that has largely been replaced in practice by medications with a better safety profile
downstream mitochondrial biogenesis and fatty acid oxidation Form: Oral capsule, 250 mcg per capsule Frequency: Once to four times daily (split dosing) Cycle: 8 weeks on, 4 weeks off (educational framework) Storage: Sealed, room temperature, dry, light-protected Dosing Protocol Weeks 12: 250 mcg once daily, taken with a small amount of dietary fat to support absorption of the lipophilic compound Weeks 36: 500 mcg daily, split into morning and afternoon doses (12 hours apart where practical) Weeks 78: Optional escalation to 7501000 mcg daily, split across 34 doses Weeks 912: Off-cycle washout Timing: Dosing alongside meals containing fat is theorized to support absorption, but no oral pharmacokinetic data exist to confirm this Consistency: Maintain the same intra-day intervals across the cycle Storage Instructions Store the sealed bottle at room temperature (1525 C / 5977 F) Keep in a dry environment, away from direct light and humidity Do not refrigerate or freeze the capsules Replace the desiccant pack if included and visibly degraded Discard if capsules show discoloration, fusion, or shell breakdown Important Notes SLU-PP-332 has no human safety, efficacy, or pharmacokinetic data All efficacy data come from animal studies using a non-oral route The compound is investigational and is not approved by any regulatory body for human use Maintain detailed research logs of dosing, timing, and observations Discontinue immediately and document any unexpected observations Intended strictly for in vitro and research-model use
For example, Trulicity (dulaglutide) has been shown to offer significant cardiovascular benefits
